Network Meta-Analysis of Randomized Controlled Trials: Efficacy and Safety of UDCA-Based Therapies in Primary Biliary Cirrhosis

AbstractMajor ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment.

[1]  L. Rodrigo,et al.  Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. , 2000, Journal of hepatology.

[2]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[3]  P. Grambsch,et al.  Prognosis in primary biliary cirrhosis: Model for decision making , 1989, Hepatology.

[4]  M. Braddock,et al.  Systematic review with network meta‐analysis: adjuvant therapy for resected biliary tract cancer , 2014, Alimentary pharmacology & therapeutics.

[5]  P. Scheuer,et al.  Multicentre randomized placebo‐controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis , 2000, Alimentary pharmacology & therapeutics.

[6]  Y. Chrétien,et al.  Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.

[7]  K. Hübner,et al.  [Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: results of a controlled study]. , 1989, Zeitschrift fur Gastroenterologie. Verhandlungsband.

[8]  A. West,et al.  A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis , 1993, Hepatology.

[9]  G. Thiéfin,et al.  Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. , 2007, Gastroenterologie clinique et biologique.

[10]  S. Kaneko,et al.  The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  M. Kurosaki,et al.  Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  O. Yokosuka,et al.  Bezafibrate treatment: a new medical approach for PBC patients? , 2003, Journal of Gastroenterology.

[13]  F. Marumo,et al.  Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. , 1996, Journal of hepatology.

[14]  B. Balkau,et al.  A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. , 1991, The New England journal of medicine.

[15]  Martin Braddock,et al.  Systematic Review With Network Meta-Analysis , 2015, Medicine.

[16]  Douglas G Altman,et al.  Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.

[17]  K. Lindor,et al.  Primary biliary cirrhosis , 1998, Springer Netherlands.

[18]  Keith Abrams,et al.  Use of Indirect and Mixed Treatment Comparisons for Technology Assessment , 2012, PharmacoEconomics.

[19]  J. Talwalkar,et al.  Primary biliary cirrhosis , 2003, The Lancet.

[20]  O. Chazouilleres,et al.  Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: Clinical features and response to therapy , 1998, Hepatology.

[21]  H. Ackermann,et al.  Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. , 1999, Gastroenterology.

[22]  B. Savaş,et al.  Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis. , 2010, Hepato-gastroenterology.

[23]  U. Steinbrecher,et al.  The canadian multicenter double‐blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis , 1994, Hepatology.

[24]  E. Dickson,et al.  Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. , 1994, Gastroenterology.

[25]  T. Therneau,et al.  Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. , 1996, Gastroenterology.

[26]  H. Ebinuma,et al.  Primary biliary cirrhosis – Autoimmune hepatitis overlap syndrome: A rationale for corticosteroids use based on a nation‐wide retrospective study in Japan , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[27]  M. Bennett,et al.  A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis , 1994, Journal of gastroenterology and hepatology.

[28]  A. West,et al.  Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis , 2005, Hepatology.

[29]  C. Chan,et al.  Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: A short‐term, randomized, double‐blind controlled, cross‐over study with long‐term follow up , 1993, Journal of gastroenterology and hepatology.

[30]  G. Gores,et al.  The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study , 1995, Hepatology.

[31]  K. Einarsson,et al.  Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. , 1997, Scandinavian journal of gastroenterology.

[32]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[33]  B. Combes,et al.  Ursodeoxycholic Acid in Primary Biliary Cirrhosis , 1997, Seminars in liver disease.

[34]  M. Allocca,et al.  Ten‐year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double‐blind, placebo‐controlled trial on symptomatic patients , 2001, Alimentary pharmacology & therapeutics.

[35]  M. Färkkilä,et al.  A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. , 1995, Gastroenterology.

[36]  M. Kaplan,et al.  Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  E. Zafrani,et al.  A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis , 1996 .

[38]  M. Cumsille,et al.  The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. , 1997, Journal of hepatology.

[39]  B. Balkau,et al.  Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. , 1994, The New England journal of medicine.

[40]  Jack Bowden,et al.  Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics , 2011, BMC medical research methodology.

[41]  C. Gluud,et al.  Bezafibrate for primary biliary cirrhosis. , 2012, The Cochrane database of systematic reviews.

[42]  J. Rodés,et al.  Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial , 2000 .

[43]  N. Welton,et al.  Addressing between‐study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non‐rheumatic atrial fibrillation , 2009, Statistics in medicine.

[44]  S. Hadziyannis,et al.  Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial , 2002, American Journal of Gastroenterology.

[45]  O. Chazouilleres,et al.  Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. , 2006, Journal of hepatology.

[46]  L. Price,et al.  A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten‐year results , 2004, Hepatology.

[47]  M. Nishioka,et al.  A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis , 1990, Gastroenterologia Japonica.

[48]  Fan Wang,et al.  Combination Therapy of Ursodeoxycholic Acid and Corticosteroids for Primary Biliary Cirrhosis with Features of Autoimmune Hepatitis: A Meta-Analysis , 2013, Gastroenterology research and practice.

[49]  F. BordaCelaya,et al.  [Primary biliary cirrhosis]. , 1989, Anales de medicina interna.

[50]  F. Bianchi,et al.  Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. , 1993, Journal of hepatology.

[51]  U. Akarca,et al.  Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. , 2002, Hepato-gastroenterology.